12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Eli Lilly sales and marketing update

Eli Lilly launched Amyvid florbetapir in 16 sites across the U.S. as a PET imaging agent to estimate beta amyloid neuritic plaque density in patients with cognitive impairment who are...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >